Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Average Recommendation of “Reduce” from Brokerages

Integra LifeSciences Holdings Co. (NASDAQ:IART) has received an average rating of “Reduce” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $23.00.

Several research analysts have commented on IART shares. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Citigroup raised their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Truist Financial decreased their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Bank of America decreased their price objective on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART opened at $22.68 on Wednesday. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -251.97, a price-to-earnings-growth ratio of 0.82 and a beta of 1.15. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $45.42. The company has a 50-day moving average price of $22.86 and a 200-day moving average price of $23.05.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. During the same period last year, the company earned $0.76 EPS. The business’s quarterly revenue was down .4% compared to the same quarter last year. As a group, equities analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Insider Transactions at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Cooke & Bieler LP lifted its position in Integra LifeSciences by 12.4% during the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock valued at $102,406,000 after purchasing an additional 388,710 shares during the period. Sachem Head Capital Management LP bought a new position in shares of Integra LifeSciences during the 3rd quarter valued at $44,153,000. Dimensional Fund Advisors LP boosted its stake in shares of Integra LifeSciences by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock worth $52,014,000 after buying an additional 12,766 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Integra LifeSciences by 15.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company’s stock worth $17,158,000 after acquiring an additional 125,620 shares during the period. Finally, D. E. Shaw & Co. Inc. increased its position in Integra LifeSciences by 64.6% during the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after acquiring an additional 335,557 shares during the last quarter. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.